Deciphering RTK-RAS and MAPK Pathway Dependencies in Gemcitabine-Treated Pancreatic Ductal Adenocarcinoma Through Conversational Artificial Intelligence
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27073011 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Fernando C Diaz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27514, USA. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Deoxycytidine, Pancreatic Neoplasms, Artificial Intelligence. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Wall Fund for Pancreatic Cancer Research at City of Hope, National Cancer Institute.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy marked by substantial molecular heterogeneity and variable response to gemcitabine-based therapy. While KRAS mutations are nearly universal, the broader RTK-RAS and MAPK signaling architecture and its relationship to treatment response remain incompletely defined. We conducted an integrative clinical-genomic analysis of 184 PDAC tumors stratified by age at diagnosis and gemcitabine exposure, interrogating somatic alterations across curated RTK-RAS/MAPK gene sets. Conversational artificial intelligence agents (AI-HOPE-RTK-RAS and AI-HOPE-MAPK) enabled dynamic cohort construction and pathway-level analyses, with findings validated using standard statistical methods. In late-onset PDAC, ERBB2 and RET mutations were significantly enriched in gemcitabine-treated tumors. Early-onset cases demonstrated differential enrichment of CACNA2D family alterations in non-treated tumors and higher frequencies of FLNB and TP53 mutations in treated disease. Importantly, late-onset patients not treated with gemcitabine who lacked RTK-RAS or MAPK alterations exhibited significantly improved overall survival. These findings reveal age- and treatment-dependent pathway dependencies beyond canonical KRAS status and support a precision oncology framework in PDAC. Conversational AI facilitated rapid, multidimensional clinical–genomic integration to uncover clinically relevant signaling substructures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27514, USA.
- Department of Integrative Translational Sciences, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA.
- City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
ORCID-Profile: Brigette Waldrup, Francisco G Carranza, Enrique Velazquez-Villarreal
Förderung
- NCI NIH HHS
- Wall Fund for Pancreatic Cancer Research at City of Hope
- National Cancer Institute
- City of Hope Cancer Control and Population Sciences Program
- Drug Development and Capacity Building: A UCR/CoH-CCC Partnership project
Zitieren
APA
Diaz, F. C., Waldrup, B., Carranza, F. G., Manjarrez, S., & Velazquez-Villarreal, E. (2026). Deciphering RTK-RAS and MAPK Pathway Dependencies in Gemcitabine-Treated Pancreatic Ductal Adenocarcinoma Through Conversational Artificial Intelligence. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27073011
Vancouver
Diaz FC, Waldrup B, Carranza FG, Manjarrez S, Velazquez-Villarreal E. Deciphering RTK-RAS and MAPK Pathway Dependencies in Gemcitabine-Treated Pancreatic Ductal Adenocarcinoma Through Conversational Artificial Intelligence. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27073011
BibTeX
@article{Diaz2026,
author = {Diaz, Fernando C and Waldrup, Brigette and Carranza, Francisco G and Manjarrez, Sophia and Velazquez-Villarreal, Enrique},
title = {Deciphering RTK-RAS and MAPK Pathway Dependencies in Gemcitabine-Treated Pancreatic Ductal Adenocarcinoma Through Conversational Artificial Intelligence},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27073011}
}
EUVIMED